Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Debt (2020 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Debt for 6 consecutive years, with $324.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 14.14% to $324.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $324.6 million, a 14.14% increase, with the full-year FY2025 number at $324.6 million, up 14.14% from a year prior.
  • Non-Current Debt was $324.6 million for Q4 2025 at ImmunityBio, up from $316.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $480.0 million in Q3 2023 to a low of $106.6 million in Q1 2024.
  • A 5-year average of $276.5 million and a median of $297.3 million in 2021 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 506.48% in 2021, then tumbled 76.85% in 2024.
  • ImmunityBio's Non-Current Debt stood at $303.2 million in 2021, then dropped by 5.1% to $287.8 million in 2022, then crashed by 45.99% to $155.4 million in 2023, then soared by 83.0% to $284.4 million in 2024, then rose by 14.14% to $324.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Debt are $324.6 million (Q4 2025), $316.1 million (Q3 2025), and $307.0 million (Q2 2025).